Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy – a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.
Phase of Trial: Phase IV
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 12 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Jul 2007 New trial record.